GSK and Pfizer: Partnering Up?


The HIV-drug alliance between GlaxoSmithKline and Pfizer is getting a lot more play in the press than I thought it would. Deals between the big pharmaceutical outfits are not rare. Merck and Schering Plough teamed up for Vytorin, and Merck similarly joined Bristol-Myers Squibb on a (failed) diabetes drug a few years ago. J&J and Bayer are partnered on a Bayer anticoagulant drug, Schering-Plough and J&J split Remicade (an agreement which is complicating S-P's current merger plans), and Pfizer had teamed up with Warner-Lambert on Lipitor before they up and bought the whole company. There have also been several joint ventures over the years, such as Takeda-Abbott and Astra-Merck.

The unusual part of this deal is that it involves a whole therapeutic area. Most deals are either smaller or larger than that: a single drug, or the whole company. And that gets to the unusual part of the whole partnership - the way that it will involve early research. When companies partner on a single drug, it's mostly a marketing arrangement: you guys take Europe, we'll take North America. No research secrets are shared; the research has been done by then. And of course, when you buy another company or merge with them, there aren't any secrets left. But this middle ground, co-researching and developing drugs in one area, could be interesting.

You'd think that the process of drug discovery would be fairly standardized, but that's true only in a broad sense. Different companies have different assays that they've validated and are comfortable with, especially in the early phases of the process. (By the time you get to FDA-level clinical data, naturally, techniques do tend to converge). And there's the whole question of research cultures - companies do have different ones, with varying ideas about what's risky and what's not, how projects should be started and progressed, and how quickly it all should happen. Two large shops like Pfizer and GSK are likely, though, to be closer to each other's style than not. And HIV research is a pretty mature field, so the chances are smaller for a single company to have a big proprietary edge in drug development. (There's a one-sentence explanation for the whole deal, actually).

So I think this could work out, if both sides take it seriously. The structure looks like GSK has a lot more involved than Pfizer, though, so one of the things to watch will be how much effort Pfizer really puts into the new venture. Lip service is just as common a currency in the drug companies as it is anywhere else, and converts at the same exchange rates.

Derek Lowe blogs from inside the drug labs at In the Pipeline.

Jump to comments
Presented by

Derek Lowe

Derek Lowe is a drug discovery chemist with 20 years of experience in the pharmaceutical industry, which is still very much his day job. He's worked on projects targeted at Alzheimer's, cancer, diabetes, infectious diseases, and other areas, but like most discovery scientists in the business, he has yet to produce a marketed drug. Explaining how and why this happens is what led to the launch of his blog, "In the Pipeline", in 2002, and the explaining continues. . .
Get Today's Top Stories in Your Inbox (preview)

A Technicolor Time-Lapse of Alaska's Northern Lights

The beauty of aurora borealis, as seen from America's last frontier

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register. blog comments powered by Disqus


A Time-Lapse of Alaska's Northern Lights

The beauty of aurora borealis, as seen from America's last frontier


What Do You Wish You Learned in College?

Ivy League academics reveal their undergrad regrets


Famous Movies, Reimagined

From Apocalypse Now to The Lord of the Rings, this clever video puts a new spin on Hollywood's greatest hits.


What Is a City?

Cities are like nothing else on Earth.


CrossFit Versus Yoga: Choose a Side

How a workout becomes a social identity


In Online Dating, Everyone's a Little Bit Racist

The co-founder of OKCupid shares findings from his analysis of millions of users' data.



More in Business

Just In